- Home
- IMTX vs DMRA Comparison
IMTX vs DMRA Comparison
Compare IMTX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | DMRA |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Germany | United States |
| Employees | 407 | 7 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMTX | DMRA |
|---|---|---|
| Price | $11.47 | $25.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $19.00 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 454.9K | 290.2K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $16.50 |
| 52 Week High | $12.41 | $28.76 |
Technical Indicators
Market Signals| Indicator | IMTX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 53.54 |
| Support Level | $9.24 | $24.80 |
| Resistance Level | $12.41 | $26.73 |
| Average True Range (ATR) | 0.60 | 1.51 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 84.09 | 80.49 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.